Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Rare Disease and Orphan Drugs Journal is Scopus-indexed (Q3, CiteScore 2.1), WoS ESCI. Published by OAE Publishing Inc..
Checked against the index lists dated .
ISSN 2771-2893Verify ISSN ↗
Publisher: OAE Publishing Inc.
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Internal Medicine | 104 / 179 | 42nd | Q3 |
| Genetics (clinical) | 77 / 100 | 23rd | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present, best quartile Q3, CiteScore 2.1.
Rare Disease and Orphan Drugs Journal is Q3 in Internal Medicine (rank 104 of 179) and Q4 in Genetics (clinical) (rank 77 of 100), by CiteScore 2025.
Rare Disease and Orphan Drugs Journal is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.1, which places it in quartile Q3 at the 42nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.385, quartile Q3, with an H-index of 7.
Rare Disease and Orphan Drugs Journal is published by OAE Publishing Inc. Its ISSN is 2771-2893.
Yes — indexed in the Emerging Sources Citation Index.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Rare Disease and Orphan Drugs Journal has an h-index of 9 and a 2-year mean of 1.5 citations per paper (OpenAlex). Its Scopus CiteScore is 2.1, quartile Q3. On 2-year citations it ranks #91 of 172 Scopus journals in Internal Medicine.
Rare Disease and Orphan Drugs Journal published 35 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 82 research articles (2023–2026), authors are most often from United States (28.5%), France (14.9%) and China (8.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.